Frank McCormick

CIK: 0001257809

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (50.0%)

Position reduction

Option Exercises (M)1 (6.3%)

Derivative conversions

Awards (A)4 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (18.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BBIO

BridgeBio Pharma, Inc.

Director

BBOT

BridgeBio Oncology Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (16 total)

BBIO
BridgeBio Pharma, Inc.
Jun 22, 2026
Award(A)
Direct
4K shares-
BBOT
BridgeBio Oncology Therapeutics, Inc.
Jun 16, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31.7K shares-
BBIO
BridgeBio Pharma, Inc.
Oct 29, 2025
Sale(S)
Indirect
3.5K shares at avg. $67.52$236K
BBIO
BridgeBio Pharma, Inc.
Oct 29, 2025
Sale(S)
Indirect
8.6K shares at avg. $68.50$589K
BBIO
BridgeBio Pharma, Inc.
Oct 29, 2025
Sale(S)
Indirect
43.4K shares at avg. $69.24$3.0M
BBIO
BridgeBio Pharma, Inc.
Oct 29, 2025
Sale(S)
Indirect
111.8K shares at avg. $65.48$7.3M
BBIO
BridgeBio Pharma, Inc.
Oct 29, 2025
Sale(S)
Indirect
31.1K shares at avg. $66.20$2.1M
BBIO
BridgeBio Pharma, Inc.
Oct 27, 2025
Sale(S)
Indirect
1.6K shares at avg. $65.00$107K
BBIO
BridgeBio Pharma, Inc.
Sep 5, 2025
Sale(S)
Direct
74K shares at avg. $53.16$3.9M
BBIO
BridgeBio Pharma, Inc.
Sep 5, 2025
Exercise(M)
Direct
74K shares at avg. $11.92$882K
BBOT
BridgeBio Oncology Therapeutics, Inc.
Aug 26, 2025
Award(A)
Stock Option (Right to Buy)
Direct
91.1K shares-
BBIO
BridgeBio Pharma, Inc.
Jun 24, 2025
Sale(S)
Indirect
100K shares at avg. $44.23$4.4M
BBIO
BridgeBio Pharma, Inc.
Jun 20, 2025
Award(A)
Direct
6.6K shares-
BBIO
BridgeBio Pharma, Inc.
May 8, 2025
Gift(G)
Direct
3K shares-
BBIO
BridgeBio Pharma, Inc.
May 7, 2025
Gift(G)
Direct
33K shares-
BBIO
BridgeBio Pharma, Inc.
Dec 26, 2024
Gift(G)
Direct
7.4K shares-

		Type	Shares	Price		Ownership
Jun 22, 2026	BBIO BridgeBio Pharma, Inc.	Award(A)	3,990	-	$0	Direct
Jun 16, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	31,675	-	-	Direct
Oct 29, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	3,497	$67.52	$236,130	Indirect
Oct 29, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	8,598	$68.50	$588,985	Indirect
Oct 29, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	43,393	$69.24	$3,004,349	Indirect
Oct 29, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	111,755	$65.48	$7,317,315	Indirect
Oct 29, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	31,116	$66.20	$2,059,749	Indirect
Oct 27, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	1,641	$65.00	$106,665	Indirect
Sep 5, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	74,000	$53.16	$3,933,544	Direct
Sep 5, 2025	BBIO BridgeBio Pharma, Inc.	Exercise(M)	74,000	$11.92	$882,080	Direct
Aug 26, 2025	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	91,076	-	-	Direct
Jun 24, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	100,000	$44.23	$4,422,800	Indirect
Jun 20, 2025	BBIO BridgeBio Pharma, Inc.	Award(A)	6,589	-	-	Direct
May 8, 2025	BBIO BridgeBio Pharma, Inc.	Gift(G)	3,000	-	-	Direct
May 7, 2025	BBIO BridgeBio Pharma, Inc.	Gift(G)	33,000	-	-	Direct
Dec 26, 2024	BBIO BridgeBio Pharma, Inc.	Gift(G)	7,400	-	$0	Direct

1-16 of 16 transactions

About MCCORMICK FRANK

MCCORMICK FRANK (SEC CIK 0001257809) files insider reports with the SEC as Director of BridgeBio Pharma, Inc. (BBIO) and Director of BridgeBio Oncology Therapeutics, Inc. (BBOT).

Signal8 holds 12 ownership filings by MCCORMICK FRANK (1 Form 3, 11 Form 4), filed between Dec 27, 2024 and Jun 24, 2026. Those filings report 16 transactions, from Dec 26, 2024 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MCCORMICK FRANK's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by MCCORMICK FRANK

Jun 22, 2026: Grant or award of BBIO shares (Form 4, code A).
Jun 16, 2026: Grant or award of BBOT derivative securities (Form 4, code A).
Oct 29, 2025: Open-market sales of BBIO shares (5 lines, Form 4, code S).
Oct 27, 2025: Open-market sale of BBIO shares (Form 4, code S).
Sep 5, 2025: Open-market sale of BBIO shares (Form 4, code S).

Other insiders filing for BridgeBio Pharma, Inc. (BBIO)

Apuli Maricel, Chief Accounting Officer
Kumar Neil, Chief Executive Officer
Trimarchi Thomas, President and CFO
Ellis Andrea, Director
Cook Jennifer E., Director
Valantine Hannah, Director

How to read Form 4 transaction codes